Regeneron PharmaceuticalsSTU:RGO -0.71%85 Dividend Yield % is 0.57% as of Jun. 26, 2026, which is 50% above its 10-year median of 0.38. GuruFocus rates STU:RGO with a GF Score™ of 85/100 and a GF Value™ of €790.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 151 Biotechnology companies, Regeneron Pharmaceuticals ranks worse than 76.82% on this metric.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RGO vs ALNY, RVMD, ONC: Dividend Yield % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Regeneron Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.940000
2026-05-20
2026-05-20
2026-06-04
Cash Dividend
quarterly
USD:EUR 0.856000
USD 0.940000
2026-02-20
2026-02-20
2026-03-05
Cash Dividend
quarterly
USD:EUR 0.846000
USD 0.880000
2025-11-20
2025-11-20
2025-12-05
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.880000
2025-08-18
2025-08-18
2025-09-03
Cash Dividend
quarterly
USD:EUR 0.859000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (STU:RGO) has a Dividend Yield % of 0.57% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Regeneron Pharmaceuticals and its competitors. This is 50% above median its historical median of 0.38. Over the past decade, Regeneron Pharmaceuticals' Dividend Yield % has ranged from 0.15 to 0.59. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #116 out of 151 companies in the Biotechnology industry, placing it in the top 76.8%.
Is Regeneron Pharmaceuticals' Dividend Yield % too high?
Regeneron Pharmaceuticals' current Dividend Yield % of 0.57% is 50% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.59. The Biotechnology industry median Dividend Yield % is 1.53. Regeneron Pharmaceuticals' value of 0.57% is 62.7% below this industry median. Based on the distribution chart, Regeneron Pharmaceuticals ranks #116 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Dividend Yield % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #116 out of 151 companies for Dividend Yield %. This places Regeneron Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.53. Regeneron Pharmaceuticals' value of 0.57% is 62.7% below this benchmark. Historically, Regeneron Pharmaceuticals' own Dividend Yield % has ranged from 0.15 to 0.59 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 1.53, Regeneron Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regeneron Pharmaceuticals's current Dividend Yield % of 0.57% is 62.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Regeneron Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regeneron Pharmaceuticals's current Dividend Yield % is 0.57%, which is 50% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €790.31, compared to a current price of €545.00 — trading 31% below its estimated fair value. The current Dividend Yield % is 0.57%, which is 50% above median its 10-year median of 0.38 and 62.7% below the Biotechnology industry median of 1.53. Regeneron Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Dividend Yield % is 0.57% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €545.00 is trading 31% below its estimated GF Value™ of €790.31.
GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for STU:RGO:
Dividend Yield %: 0.57% (50% above median its 10-year median of 0.38)
GF Value™: €790.31 vs. price of €545.00 (31% below fair value)
Industry Position: 62.7% below the Biotechnology median (#116 of 151)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
85GF Score
Get the complete analysis for STU:RGO
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
